Tag: Omacetaxine mepesuccinate

According to the U.S. Food and Drug Administration (FDA), the generic name for Synribo is omacetaxine mepesuccinate. This medication was developed to treat certain forms of chronic myeloid leukemia (CML) in patients who had become resistant to or intolerant of other therapies. It is important to note that Synribo has been permanently discontinued and is no longer available in the U.S. market.

Synribo (omacetaxine mepesuccinate) was permanently discontinued due to manufacturing issues, with remaining inventory expected to be exhausted in late 2023. This article explores the detailed reasons for its withdrawal and its place in cancer therapy.